Pramlintide is a prescription medicine that copies amylin — a hormone your pancreas normally releases alongside insulin when you eat. Taken as a small injection before meals, it slows how fast food leaves the stomach, lowers a post-meal hormone (glucagon) that raises blood sugar, and helps you feel full sooner. It is FDA-approved as an add-on to mealtime insulin for adults with type 1 or insulin-treated type 2 diabetes. It is not a casual "research peptide": it carries a boxed warning for severe low blood sugar and must be managed by a diabetes clinician.
Pramlintide is a synthetic 37-amino-acid amylin analog and an adjunct to mealtime insulin for type 1 or insulin-treated type 2 diabetes not at goal despite optimized insulin. It slows gastric emptying, suppresses postprandial glucagon, and increases satiety, reducing post-meal glucose excursions and supporting weight neutrality or modest loss. Its boxed warning is severe insulin-associated hypoglycemia — most likely within 3 hours of injection — so initiation requires a 50% mealtime-insulin reduction, careful patient selection, and glucose monitoring. It is contraindicated in gastroparesis and hypoglycemia unawareness.
Pramlintide (Lys-[Pro²⁵,²⁸,²⁹]-amylin; C₁₇₁H₂₆₇N₅₁O₅₃S₂, MW ≈ 3949.4 Da, CAS 151126-32-8, PubChem CID 16132446) is human amylin re-engineered with three proline substitutions that disrupt the β-sheet packing responsible for amyloid aggregation, yielding a soluble, injectable analog. It activates amylin receptors — calcitonin-receptor cores complexed with RAMP1/2/3 — in the area postrema. With a short ~48-minute half-life and renal clearance, it requires pre-meal dosing; its short action is exactly what next-generation long-acting amylin analogs such as cagrilintide were engineered to overcome, making pramlintide the proof-of-concept for today's amylin renaissance.
Pramlintide is one of the strongest-evidence entries in this atlas because it is FDA-approved and fully label-defined — but also one of the highest-risk, because it is used with insulin and carries a boxed warning for severe hypoglycemia. It is a mealtime neuroendocrine adjunct that controls how glucose appears after eating; it is not insulin, not a GLP-1 agonist, and not an SGLT2 inhibitor.
Healthy beta cells release two hormones after a meal: insulin and amylin. In insulin-dependent diabetes the amylin signal is lost along with insulin. Pramlintide replaces it — a soluble, non-aggregating copy of amylin that re-instates three coordinated brakes on how fast glucose appears in the blood after eating.
| Mechanism | Strength | Basis |
|---|---|---|
| Delayed gastric emptying | High | Label-supported |
| Postprandial glucagon suppression | High | Label + human pharmacology |
| Reduced post-meal glucose excursions | High | Label + RCTs |
| Satiety / reduced caloric intake | Mod–high | Label + obesity studies |
| Weight reduction | Moderate | Secondary outcome |
| Insulin-sparing | Moderate | Requires clinician-managed insulin reduction |
| Position | Human amylin | Pramlintide | Effect |
|---|---|---|---|
| 25 | Alanine | Proline | Breaks β-sheet |
| 28 | Serine | Proline | Breaks β-sheet |
| 29 | Serine | Proline | Breaks β-sheet |
| Net result | Aggregates (amyloid) | Soluble, stable | Druggable analog |
Pramlintide has two distinct label protocols — one for type 1 and one for type 2 diabetes — both built on the same principles: reduce mealtime insulin first, start low, and step up only when nausea is tolerable. The panels below separate the type-1 and type-2 schedules, administration mechanics, the nausea-gated titration logic, and the off-label obesity research context. Every figure here is label education, not a personalized dose. Insulin and pramlintide adjustments must be directed by a clinician skilled in insulin use.
| Step | Dose | Advance when |
|---|---|---|
| Initiation | 15 µg pre-meal | + 50% mealtime-insulin cut |
| Step 2 | 30 µg | ≥ 3 days without significant nausea |
| Step 3 | 45 µg | ≥ 3 days without significant nausea |
| Target | 60 µg | Maintenance if tolerated |
| Step | Dose | Advance when |
|---|---|---|
| Initiation | 60 µg pre-meal | + 50% mealtime-insulin cut |
| Target | 120 µg | ≥ 3 days without significant nausea |
| Field | Value | Source |
|---|---|---|
| Concentration | 1000 µg/mL (SymlinPen) | Label |
| Storage (unopened) | 2–8 °C, no freeze, protect light | Label |
| Storage (in use) | ≤30 °C up to 30 days | Label |
| Mix with insulin | Never | Label |
| Pen sharing | Never | Label |
| Signal | Action | Gate |
|---|---|---|
| ≥ 3 days no significant nausea | Step pramlintide up | Tolerance |
| Significant nausea | Hold / step down | Tolerance |
| Post-dose lows | Reduce insulin (clinician) | Safety |
| Recurrent severe hypo | Reassess / discontinue | Safety |
| Context | Status | Grade |
|---|---|---|
| Mealtime adjunct (T1D/T2D) | FDA-approved | A |
| Weight benefit (with insulin) | Secondary outcome | B |
| Obesity-only therapy | Off-label / research | C |
Reference only — shows the published label titration doses and the corresponding pen volume from the 1000 µg/mL SymlinPen. It does not generate personalized dosing, insulin adjustments, or treatment recommendations, and is not medical advice. All initiation and titration must be directed by a clinician skilled in insulin use, with the mandatory 50% mealtime-insulin reduction at start.
Pramlintide's only approved "combination" is with insulin — which is also its highest-risk pairing. Beyond that, the logic is about hazards: drugs that compound hypoglycemia, drugs whose absorption is delayed by slowed gastric emptying, and mechanistic overlaps (GLP-1/GIP agents) that amplify nausea and gastric effects. There is no casual performance or longevity stack here.
| Element | Requirement | Grade |
|---|---|---|
| Mealtime insulin | Cut 50% at start | A |
| Injection | Separate site, never mixed | A |
| Category | Concern | Action |
|---|---|---|
| Sulfonylureas / antidiabetics | ↑ hypoglycemia | Reduce / monitor |
| ACE-I, fibrates, MAOIs, salicylates | ↑ susceptibility | Monitor glucose |
| Drug type | Concern | Action |
|---|---|---|
| Fast-acting analgesics | Delayed onset | Take ≥1 h before |
| Threshold-dependent orals | Altered absorption | Separate timing |
| Agent | Conflict | Status |
|---|---|---|
| GI motility stimulants | Opposes mechanism | Exclude |
| Overlap | Risk | Status |
|---|---|---|
| Gastric emptying | Additive slowing | Review only |
| Appetite / intake | Additive ↓ intake | Review only |
| Factor | Concern | Action |
|---|---|---|
| SGLT2 + T1D | DKA / intake risk | High caution |
| Factor | Concern | Action |
|---|---|---|
| Alcohol | ↑ hypoglycemia | Caution / avoid acutely |
| Use | Status | Reason |
|---|---|---|
| Self-directed dosing | Blocked | Boxed-warning risk |
| Non-Rx sale language | Blocked | Prescription drug |
Pramlintide's safety profile is dominated by one issue — severe insulin-associated hypoglycemia — wrapped around a tolerability problem (nausea) that limits dosing. Everything in the protocol (insulin reduction, slow titration, patient selection, contraindications) exists to manage these two realities.
| Population | Pramlintide | Placebo | Source |
|---|---|---|---|
| Type 1 diabetes | ~48% | ~17% | Label |
| Insulin-treated type 2 | ~28% | ~12% | Label |
Review HbA1c (label says assess before starting), hypoglycemia history (recurrent severe hypo in prior 6 months is an exclusion), hypoglycemia awareness, gastroparesis screen, medication list, weight/BMI, and renal function. Confirm reliable glucose monitoring and self-management capability.
Pre- and post-meal glucose, CGM time-below-range, nausea/vomiting, and meal-intake consistency. Advance dose only after ≥3 days without significant nausea; cut insulin proactively to prevent post-dose lows.
Track A1c and postprandial glucose for efficacy; body weight as a secondary outcome; recurrent unexplained severe hypoglycemia or worsening GI symptoms should trigger a discontinuation review.
| Marker | Why it matters | Gate |
|---|---|---|
| HbA1c | Glycemic control; assess before initiation | Selection |
| CGM time-below-range | Hypoglycemia risk | Safety |
| Postprandial glucose | Primary therapeutic target | Response |
| Severe-hypoglycemia history | Recurrent severe hypo = exclusion | Safety gate |
| Gastroparesis screen | Confirmed gastroparesis contraindicated | Contraindication |
| eGFR | Risk context; ESRD not studied | Caution |
| Body weight | Secondary metabolic outcome | Monitor |
| Amplifier | Why it raises risk | Mitigation |
|---|---|---|
| Concomitant mealtime insulin | Core boxed-warning interaction | 50% insulin cut at start |
| First 3 hours post-dose | Peak severe-hypoglycemia window | Glucose check; avoid driving |
| Reduced food intake / nausea | Insulin–intake mismatch | Skip dose if meal skipped |
| Sulfonylureas | Additive hypoglycemia | Reduce / monitor |
| Alcohol | ↓ awareness, ↑ lows | Caution / avoid acutely |
| Type 1 diabetes | Highest-risk population | Strict monitoring + selection |
| Condition | Concern | Severity · grade |
|---|---|---|
| Hypoglycemia unawareness | Severe lows may go undetected | Contraindicated |
| Confirmed gastroparesis | Pramlintide further slows gastric emptying | Contraindicated |
| Serious hypersensitivity to Symlin/components | Allergy risk | Contraindicated |
| Recurrent severe hypoglycemia (prior 6 mo) | Should not be considered | Exclude |
| Poor glucose-monitoring adherence | Cannot manage hypo risk | Exclude |
| Poor insulin adherence | Unsafe titration context | Exclude |
| HbA1c > 9% | Should not be considered | Exclude |
| Need for GI-motility drugs | Conflicts with mechanism | Exclude |
| Pediatric use | Safety/efficacy not established | Not recommended |
| Older adults | Greater sensitivity not ruled out | Caution |
| ESRD / dialysis | Not studied (mild–severe RI: no dose change) | Caution |
| Hepatic impairment | Not studied | Caution |
| Concomitant sulfonylureas | Additive hypoglycemia | Monitor |
| Alcohol use | ↑ hypoglycemia / impaired awareness | Caution |
| Skipped meals / reduced intake | Insulin-mismatch hypo | Skip dose |
| Driving / hazardous activity post-dose | Injury risk during severe hypo | High caution |
| Pregnancy / lactation | Limited human data | Caution |
| Autonomous / non-Rx use | Boxed-warning drug | Avoid |
| Intercurrent illness / vomiting | Reduced intake + insulin = hypo / dehydration | Hold / reassess |
| Concomitant GLP-1 / GIP agent | Additive GI & intake effects | Review only |
Pramlintide's diabetes evidence is solid and label-grade: randomized trials in both type 1 and insulin-treated type 2 diabetes showing reduced postprandial glucose, modest A1c improvement, and weight benefit. Its larger legacy is mechanistic — it proved that re-instating amylin signaling works, opening the door to the long-acting analogs now reshaping obesity medicine.
The approved label defines the amylin-analog identity (37-aa, Pro²⁵’²⁸’²⁹, MW 3949.4), the type-1 and type-2 titration protocols, the mandatory 50% mealtime-insulin reduction, the boxed warning for severe hypoglycemia, contraindications, nausea rates, and the drug-interaction and administration rules — the backbone of this page.
Randomized controlled trials in type 1 diabetes showed that pramlintide dose escalation with reduced mealtime insulin improved postprandial glucose excursions and body-weight outcomes not achieved by insulin alone, with a 1-year trial concluding that amylin replacement improved long-term glycemic and weight control.
A 16-week randomized trial reported greater A1c reduction with pramlintide than placebo, reduced postprandial glucose increments, and weight loss versus weight gain in the placebo arm; longer-term data support 120 µg twice-to-thrice daily as an adjunct improving glycemic and weight control.
A 12-month study in subjects with obesity found pramlintide combined with lifestyle intervention helped achieve greater initial weight loss and improved maintenance — research evidence for the satiety mechanism, but outside the approved diabetes indication and not an Intrasigna-endorsed obesity use.
Amylin receptors (AMY₁₋₃) are calcitonin-receptor cores complexed with RAMP1/2/3, a GPCR architecture whose pharmacology pramlintide exploits in the area postrema. This receptor biology defines the satiety and gastric-emptying effects and is the mechanistic anchor for all amylin-analog development.
Cagrilintide is a once-weekly lipidated amylin analog engineered to overcome pramlintide's short half-life; combined with semaglutide as CagriSema it reached ~20.4% weight loss in the 68-week REDEFINE 1 phase-3 trial (vs 14.9% semaglutide, 11.5% cagrilintide alone), with a dedicated cagrilintide monotherapy program (RENEW) launched.
Amycretin folds GLP-1 and amylin receptor agonism into one molecule; a 2025 phase-1b/2a subcutaneous trial reported up to ~24% body-weight reduction at 36 weeks versus ~1% placebo. The same amylin mechanism pramlintide pioneered, now in a long-acting single-agent format.
A 2025 wave of amylin programs — cagrilintide, petrelintide (Zealand/Roche), eloralintide (Lilly), amycretin and AZD6234 — situates amylin as the first validated mechanism to add weight loss on top of GLP-1, with pramlintide recognized as the original clinical proof that amylin-receptor agonism is druggable. A 2025 review situates the field.
Chemical and pharmacokinetic records: C₁₇₁H₂₆₇N₅₁O₅₃S₂, MW 3949.44, CAS 151126-32-8 (acetate 196078-30-5), CID 16132446, DrugBank DB01278, ATC A10BX05; bioavailability 30–40%, protein binding ~60%, renal metabolism, half-life ~48 min.
The label's clinical-pharmacology section establishes that amylin is stored with insulin in beta-cell granules and co-secreted in response to food, tracking insulin's fasting and postprandial pattern. In insulin-deficient diabetes both signals are lost — the deficit pramlintide is designed to correct, explaining why it is dosed alongside mealtime insulin.
Slowed gastric emptying controls the rate of glucose appearance while postprandial glucagon suppression reduces hepatic glucose output — two label-supported, mechanistically distinct contributions to lower postprandial glucose that insulin alone does not fully restore.
The boxed-warning risk is managed structurally: mealtime insulin is reduced by 50% at initiation and re-optimized only once a stable pramlintide dose is reached, with severe hypoglycemia most likely within 3 hours of dosing. This single rule is the most important safety lever in the protocol.
Nausea is the dose-limiting effect: ~48% in type 1 vs 17% placebo, and ~28% vs 12% in insulin-treated type 2. The label's stepwise schedule advances only after ≥3 days without clinically significant nausea — converting a tolerability problem into a structured titration rule.
Two interaction themes define safe use: agents that add to hypoglycemia risk (sulfonylureas, ACE inhibitors, fibrates, MAOIs, salicylates, somatostatin analogs) and delayed oral-drug absorption from slowed gastric emptying — separate critical fast-acting orals by 1 h before or 2 h after.
No dose adjustment is required across mild–severe renal impairment, but ESRD/dialysis was not studied; hepatic impairment was not studied; pediatric safety/efficacy is not established and greater sensitivity in older adults cannot be ruled out — bounding the populations in which the test is appropriate.
Beyond cagrilintide, Roche/Zealand's petrelintide and Lilly's eloralintide are advancing long-acting amylin analogs as potential GLP-1 alternatives, with eloralintide phase-2 monotherapy reaching ~20% weight loss. Nearly every major pharma now holds an amylin program — an industry alignment pramlintide's mechanism made possible.
Pramlintide is often mistaken for a GLP-1 drug — it is not. It is a mealtime amylin replacement, mechanistically and practically distinct: multiple daily pre-meal injections rather than weekly dosing, used with insulin rather than instead of it. Its truest peers are the new amylin analogs it inspired, where its short action and injection burden have been engineered away.
| Agent | Class | Main role | Dosing | Hypo risk | Status |
|---|---|---|---|---|---|
| Pramlintide | Amylin analog | Mealtime insulin adjunct (T1D/T2D) | Pre-meal SC, multiple daily | High (with insulin) | FDA-approved (2005) |
| Semaglutide | GLP-1 RA | T2D & obesity | Weekly SC / oral | Low alone | FDA-approved |
| Tirzepatide | GIP/GLP-1 | T2D & obesity | Weekly SC | Low alone | FDA-approved |
| Retatrutide | GIP/GLP-1/glucagon | Obesity (investigational) | Weekly SC | Low alone | Phase 3 |
| Cagrilintide | Long-acting amylin | Obesity (mono / CagriSema) | Weekly SC | Low alone | Phase 3 (RENEW) |
| Petrelintide | Long-acting amylin | Obesity (investigational) | Weekly SC | Low alone | Phase 2 (Roche/Zealand) |
| Amycretin | GLP-1/amylin co-agonist | Obesity / T2D (investigational) | SC / oral | Low alone | Phase 2 |
| Feature | Pramlintide (amylin) | GLP-1 / GIP agents |
|---|---|---|
| Receptor | Amylin (CTR + RAMP) | GLP-1 (± GIP) receptors |
| T1D use | FDA-approved adjunct | Generally not approved for T1D glycemia |
| Dosing | Before every major meal | Usually weekly (newer agents) |
| Used with insulin | Yes — by design | Sometimes; higher hypo risk if so |
| Boxed warning | Severe hypoglycemia (with insulin) | Product-specific (e.g., thyroid C-cell) |
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. Pramlintide's FDA label and randomized diabetes trials are its firmest evidence; obesity and next-generation amylin sources provide research and frontier context; database and pharmacokinetic records define identity and disposition.